nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Alkylating Activity—Estramustine—prostate cancer	0.564	1	CiPCiCtD
Melphalan—SLC22A3—prostate cancer	0.248	1	CbGaD
Melphalan—SLC22A3—Estradiol—prostate cancer	0.0638	1	CbGbCtD
Melphalan—SLC7A5—Amino acid transport across the plasma membrane—SLC7A1—prostate cancer	0.00178	0.0709	CbGpPWpGaD
Melphalan—SLC7A5—prostate gland—prostate cancer	0.00175	0.143	CbGeAlD
Melphalan—SLC22A3—Abacavir transmembrane transport—SLC22A1—prostate cancer	0.00162	0.0646	CbGpPWpGaD
Melphalan—SLC7A5—seminal vesicle—prostate cancer	0.00148	0.121	CbGeAlD
Melphalan—SLC7A5—epithelium—prostate cancer	0.00128	0.105	CbGeAlD
Melphalan—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00123	0.0492	CbGpPWpGaD
Melphalan—SLC7A5—urethra—prostate cancer	0.00117	0.0959	CbGeAlD
Melphalan—SLC7A5—Basigin interactions—ITGA6—prostate cancer	0.00113	0.045	CbGpPWpGaD
Melphalan—SLC22A3—Organic cation transport—SLC22A1—prostate cancer	0.00111	0.0443	CbGpPWpGaD
Melphalan—SLC22A3—prostate gland—prostate cancer	0.00108	0.0889	CbGeAlD
Melphalan—Chlorambucil—GSTP1—prostate cancer	0.000971	0.468	CrCbGaD
Melphalan—SLC22A3—Abacavir transport and metabolism—SLC22A1—prostate cancer	0.000931	0.0371	CbGpPWpGaD
Melphalan—SLC22A3—seminal vesicle—prostate cancer	0.000917	0.0752	CbGeAlD
Melphalan—SLC7A5—bone marrow—prostate cancer	0.0009	0.0738	CbGeAlD
Melphalan—SLC7A5—testis—prostate cancer	0.000769	0.0631	CbGeAlD
Melphalan—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.000755	0.0301	CbGpPWpGaD
Melphalan—SLC22A3—renal system—prostate cancer	0.000739	0.0606	CbGeAlD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000727	0.0289	CbGpPWpGaD
Melphalan—SLC22A3—urethra—prostate cancer	0.000726	0.0595	CbGeAlD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—GSTA2—prostate cancer	0.000618	0.0246	CbGpPWpGaD
Melphalan—SLC7A5—lymph node—prostate cancer	0.000558	0.0457	CbGeAlD
Melphalan—SLC7A5—Desoximetasone—Prednisone—prostate cancer	0.000554	1	CbGdCrCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—AHR—prostate cancer	0.000539	0.0215	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NFE2L2—prostate cancer	0.000526	0.0209	CbGpPWpGaD
Melphalan—SLC22A3—testis—prostate cancer	0.000477	0.0392	CbGeAlD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000457	0.0182	CbGpPWpGaD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000457	0.0182	CbGpPWpGaD
Melphalan—L-Tyrosine—TH—prostate cancer	0.000443	0.213	CrCbGaD
Melphalan—SLC7A5—Basigin interactions—CAV1—prostate cancer	0.000387	0.0154	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NQO1—prostate cancer	0.00038	0.0151	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ITGA6—prostate cancer	0.000376	0.015	CbGpPWpGaD
Melphalan—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000374	0.0149	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1B1—prostate cancer	0.000364	0.0145	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NCOA1—prostate cancer	0.000348	0.0138	CbGpPWpGaD
Melphalan—SLC22A3—lymph node—prostate cancer	0.000346	0.0284	CbGeAlD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000325	0.0129	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—GRB7—prostate cancer	0.000292	0.0116	CbGpPWpGaD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000288	0.0115	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—BAX—prostate cancer	0.000284	0.0113	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1A1—prostate cancer	0.000276	0.011	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000257	0.0102	CbGpPWpGaD
Melphalan—L-Phenylalanine—TH—prostate cancer	0.000257	0.124	CrCbGaD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.00022	0.00877	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HBG1—prostate cancer	0.000209	0.0083	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000204	0.00812	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000204	0.00812	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HBG2—prostate cancer	0.000177	0.00706	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TMSB4X—prostate cancer	0.000177	0.00706	CbGpPWpGaD
Melphalan—Ibuprofen—BCL2—prostate cancer	0.000169	0.0812	CrCbGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000166	0.00659	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000166	0.00659	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000165	0.00657	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CDKN1B—prostate cancer	0.000156	0.00619	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL2—prostate cancer	0.000152	0.00606	CbGpPWpGaD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000151	0.00602	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ITGB3—prostate cancer	0.00015	0.00595	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—STX4—prostate cancer	0.000145	0.00576	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—RAD51B—prostate cancer	0.000145	0.00576	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EP300—prostate cancer	0.000137	0.00544	CbGpPWpGaD
Melphalan—Ibuprofen—CXCL8—prostate cancer	0.000135	0.0651	CrCbGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000135	0.00537	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—SRC—prostate cancer	0.000133	0.00529	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000131	0.00521	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000131	0.0052	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—F9—prostate cancer	0.00013	0.00518	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—CAV1—prostate cancer	0.000129	0.00512	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TGFB1—prostate cancer	0.000119	0.00473	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EGFR—prostate cancer	0.000116	0.00463	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000106	0.00424	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000104	0.00414	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000104	0.00414	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000104	0.00413	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000104	0.00413	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITGA6—prostate cancer	0.000102	0.00405	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	9.84e-05	0.00392	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CD9—prostate cancer	9.58e-05	0.00381	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CB—prostate cancer	8.98e-05	0.00357	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CLU—prostate cancer	8.66e-05	0.00345	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC7A1—prostate cancer	8.41e-05	0.00335	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC22A3—prostate cancer	8.41e-05	0.00335	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GRB7—prostate cancer	7.92e-05	0.00315	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.76e-05	0.00309	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GNG5—prostate cancer	7.53e-05	0.003	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—SRC—prostate cancer	7.19e-05	0.00286	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	6.87e-05	0.00274	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC22A1—prostate cancer	6.86e-05	0.00273	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC39A1—prostate cancer	6.65e-05	0.00265	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—GNG5—prostate cancer	6.52e-05	0.0026	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PRKACB—prostate cancer	6.42e-05	0.00256	CbGpPWpGaD
Melphalan—Ibuprofen—CYP2C19—prostate cancer	6.34e-05	0.0305	CrCbGaD
Melphalan—SLC7A5—Hemostasis—THBS1—prostate cancer	6.26e-05	0.00249	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PRKCZ—prostate cancer	6.06e-05	0.00241	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—KRAS—prostate cancer	5.96e-05	0.00237	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.56e-05	0.00221	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—prostate cancer	5.47e-05	0.00218	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CYP7B1—prostate cancer	5.42e-05	0.00216	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC26A4—prostate cancer	5.28e-05	0.0021	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC12A2—prostate cancer	5.28e-05	0.0021	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.24e-05	0.00209	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PRKCQ—prostate cancer	5.15e-05	0.00205	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PLAUR—prostate cancer	5.09e-05	0.00203	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	5.01e-05	0.002	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5e-05	0.00199	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HAO1—prostate cancer	4.83e-05	0.00192	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—VAV3—prostate cancer	4.72e-05	0.00188	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITPR1—prostate cancer	4.58e-05	0.00182	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.42e-05	0.00176	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—RXRA—prostate cancer	4.2e-05	0.00167	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITGB3—prostate cancer	4.05e-05	0.00161	CbGpPWpGaD
Melphalan—Decreased appetite—Mitoxantrone—prostate cancer	4.01e-05	0.000481	CcSEcCtD
Melphalan—Arrhythmia—Docetaxel—prostate cancer	4.01e-05	0.000481	CcSEcCtD
Melphalan—Chest pain—Etoposide—prostate cancer	4e-05	0.000481	CcSEcCtD
Melphalan—Fatigue—Mitoxantrone—prostate cancer	3.98e-05	0.000477	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	3.98e-05	0.000477	CcSEcCtD
Melphalan—Vomiting—Goserelin—prostate cancer	3.97e-05	0.000477	CcSEcCtD
Melphalan—Alopecia—Docetaxel—prostate cancer	3.97e-05	0.000476	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCG5—prostate cancer	3.95e-05	0.00157	CbGpPWpGaD
Melphalan—Pain—Mitoxantrone—prostate cancer	3.95e-05	0.000474	CcSEcCtD
Melphalan—Ibuprofen—PTGS2—prostate cancer	3.95e-05	0.019	CrCbGaD
Melphalan—Rash—Goserelin—prostate cancer	3.94e-05	0.000473	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PSAT1—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TST—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GRHL1—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CSAD—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CBR1—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ADI1—prostate cancer	3.94e-05	0.00157	CbGpPWpGaD
Melphalan—Dermatitis—Goserelin—prostate cancer	3.94e-05	0.000472	CcSEcCtD
Melphalan—Vomiting—Conjugated Estrogens—prostate cancer	3.94e-05	0.000472	CcSEcCtD
Melphalan—Urticaria—Estradiol—prostate cancer	3.94e-05	0.000472	CcSEcCtD
Melphalan—Immune system disorder—Capecitabine—prostate cancer	3.93e-05	0.000471	CcSEcCtD
Melphalan—Mediastinal disorder—Capecitabine—prostate cancer	3.92e-05	0.00047	CcSEcCtD
Melphalan—Rash—Conjugated Estrogens—prostate cancer	3.9e-05	0.000468	CcSEcCtD
Melphalan—Dermatitis—Conjugated Estrogens—prostate cancer	3.9e-05	0.000468	CcSEcCtD
Melphalan—Haemoglobin—Prednisone—prostate cancer	3.89e-05	0.000467	CcSEcCtD
Melphalan—Arrhythmia—Capecitabine—prostate cancer	3.88e-05	0.000466	CcSEcCtD
Melphalan—Haemorrhage—Prednisone—prostate cancer	3.87e-05	0.000465	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—prostate cancer	3.85e-05	0.000462	CcSEcCtD
Melphalan—Alopecia—Capecitabine—prostate cancer	3.84e-05	0.000461	CcSEcCtD
Melphalan—Anaphylactic shock—Etoposide—prostate cancer	3.84e-05	0.000461	CcSEcCtD
Melphalan—Infection—Etoposide—prostate cancer	3.81e-05	0.000458	CcSEcCtD
Melphalan—Connective tissue disorder—Prednisone—prostate cancer	3.81e-05	0.000457	CcSEcCtD
Melphalan—Thrombocytopenia—Etoposide—prostate cancer	3.76e-05	0.000451	CcSEcCtD
Melphalan—Tachycardia—Etoposide—prostate cancer	3.75e-05	0.00045	CcSEcCtD
Melphalan—Liver function test abnormal—Doxorubicin—prostate cancer	3.74e-05	0.000449	CcSEcCtD
Melphalan—Skin disorder—Etoposide—prostate cancer	3.73e-05	0.000447	CcSEcCtD
Melphalan—Nausea—Goserelin—prostate cancer	3.71e-05	0.000445	CcSEcCtD
Melphalan—Nausea—Conjugated Estrogens—prostate cancer	3.68e-05	0.000441	CcSEcCtD
Melphalan—Urticaria—Mitoxantrone—prostate cancer	3.67e-05	0.00044	CcSEcCtD
Melphalan—SLC22A3—Metabolism—UGT2B15—prostate cancer	3.66e-05	0.00146	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—UGT2B17—prostate cancer	3.66e-05	0.00146	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GRHPR—prostate cancer	3.66e-05	0.00146	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CKMT2—prostate cancer	3.66e-05	0.00146	CbGpPWpGaD
Melphalan—Anorexia—Etoposide—prostate cancer	3.66e-05	0.000439	CcSEcCtD
Melphalan—Hypersensitivity—Estradiol—prostate cancer	3.65e-05	0.000438	CcSEcCtD
Melphalan—Anaemia—Docetaxel—prostate cancer	3.61e-05	0.000434	CcSEcCtD
Melphalan—Flushing—Prednisone—prostate cancer	3.59e-05	0.000431	CcSEcCtD
Melphalan—Pancytopenia—Epirubicin—prostate cancer	3.59e-05	0.000431	CcSEcCtD
Melphalan—Hypotension—Etoposide—prostate cancer	3.59e-05	0.00043	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—PLAU—prostate cancer	3.57e-05	0.00142	CbGpPWpGaD
Melphalan—Asthenia—Estradiol—prostate cancer	3.55e-05	0.000426	CcSEcCtD
Melphalan—Neutropenia—Epirubicin—prostate cancer	3.54e-05	0.000425	CcSEcCtD
Melphalan—Pruritus—Estradiol—prostate cancer	3.5e-05	0.000421	CcSEcCtD
Melphalan—Leukopenia—Docetaxel—prostate cancer	3.5e-05	0.00042	CcSEcCtD
Melphalan—Anaemia—Capecitabine—prostate cancer	3.5e-05	0.00042	CcSEcCtD
Melphalan—Immune system disorder—Prednisone—prostate cancer	3.5e-05	0.00042	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC22A1—prostate cancer	3.49e-05	0.00139	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CAV1—prostate cancer	3.49e-05	0.00139	CbGpPWpGaD
Melphalan—Arrhythmia—Prednisone—prostate cancer	3.46e-05	0.000415	CcSEcCtD
Melphalan—Paraesthesia—Etoposide—prostate cancer	3.45e-05	0.000414	CcSEcCtD
Melphalan—SLC22A3—Metabolism—NAGLU—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—RFK—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTM3—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AOX1—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MBTPS1—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SULT2B1—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PGAM2—prostate cancer	3.44e-05	0.00137	CbGpPWpGaD
Melphalan—Dyspnoea—Etoposide—prostate cancer	3.42e-05	0.000411	CcSEcCtD
Melphalan—Alopecia—Prednisone—prostate cancer	3.42e-05	0.000411	CcSEcCtD
Melphalan—Cough—Docetaxel—prostate cancer	3.41e-05	0.000409	CcSEcCtD
Melphalan—Hypersensitivity—Mitoxantrone—prostate cancer	3.4e-05	0.000408	CcSEcCtD
Melphalan—Diarrhoea—Estradiol—prostate cancer	3.39e-05	0.000407	CcSEcCtD
Melphalan—Leukopenia—Capecitabine—prostate cancer	3.39e-05	0.000407	CcSEcCtD
Melphalan—Convulsion—Docetaxel—prostate cancer	3.39e-05	0.000406	CcSEcCtD
Melphalan—Decreased appetite—Etoposide—prostate cancer	3.34e-05	0.0004	CcSEcCtD
Melphalan—Myalgia—Docetaxel—prostate cancer	3.33e-05	0.000399	CcSEcCtD
Melphalan—Chest pain—Docetaxel—prostate cancer	3.33e-05	0.000399	CcSEcCtD
Melphalan—Pancytopenia—Doxorubicin—prostate cancer	3.33e-05	0.000399	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—GNG5—prostate cancer	3.32e-05	0.00132	CbGpPWpGaD
Melphalan—Gastrointestinal disorder—Etoposide—prostate cancer	3.31e-05	0.000398	CcSEcCtD
Melphalan—Asthenia—Mitoxantrone—prostate cancer	3.31e-05	0.000397	CcSEcCtD
Melphalan—Fatigue—Etoposide—prostate cancer	3.31e-05	0.000397	CcSEcCtD
Melphalan—Neuropathy peripheral—Epirubicin—prostate cancer	3.31e-05	0.000397	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.31e-05	0.000397	CcSEcCtD
Melphalan—Cough—Capecitabine—prostate cancer	3.3e-05	0.000396	CcSEcCtD
Melphalan—Stomatitis—Epirubicin—prostate cancer	3.29e-05	0.000395	CcSEcCtD
Melphalan—Jaundice—Epirubicin—prostate cancer	3.29e-05	0.000395	CcSEcCtD
Melphalan—Pain—Etoposide—prostate cancer	3.28e-05	0.000394	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—prostate cancer	3.27e-05	0.000393	CcSEcCtD
Melphalan—SLC22A3—Metabolism—AMACR—prostate cancer	3.26e-05	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP3A43—prostate cancer	3.26e-05	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SRD5A2—prostate cancer	3.26e-05	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—DEGS1—prostate cancer	3.26e-05	0.0013	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NAT1—prostate cancer	3.26e-05	0.0013	CbGpPWpGaD
Melphalan—Myalgia—Capecitabine—prostate cancer	3.22e-05	0.000387	CcSEcCtD
Melphalan—Chest pain—Capecitabine—prostate cancer	3.22e-05	0.000387	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—PPARA—prostate cancer	3.21e-05	0.00128	CbGpPWpGaD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.2e-05	0.000384	CcSEcCtD
Melphalan—Hepatobiliary disease—Epirubicin—prostate cancer	3.19e-05	0.000383	CcSEcCtD
Melphalan—Oedema—Docetaxel—prostate cancer	3.19e-05	0.000383	CcSEcCtD
Melphalan—Anaphylactic shock—Docetaxel—prostate cancer	3.19e-05	0.000383	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—PIK3CG—prostate cancer	3.18e-05	0.00126	CbGpPWpGaD
Melphalan—Infection—Docetaxel—prostate cancer	3.17e-05	0.00038	CcSEcCtD
Melphalan—Diarrhoea—Mitoxantrone—prostate cancer	3.16e-05	0.000379	CcSEcCtD
Melphalan—Vomiting—Estradiol—prostate cancer	3.15e-05	0.000378	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—EGF—prostate cancer	3.14e-05	0.00125	CbGpPWpGaD
Melphalan—Thrombocytopenia—Docetaxel—prostate cancer	3.12e-05	0.000375	CcSEcCtD
Melphalan—Rash—Estradiol—prostate cancer	3.12e-05	0.000375	CcSEcCtD
Melphalan—Dermatitis—Estradiol—prostate cancer	3.12e-05	0.000374	CcSEcCtD
Melphalan—Anaemia—Prednisone—prostate cancer	3.12e-05	0.000374	CcSEcCtD
Melphalan—SLC22A3—Metabolism—HSD17B1—prostate cancer	3.11e-05	0.00124	CbGpPWpGaD
Melphalan—Tachycardia—Docetaxel—prostate cancer	3.11e-05	0.000374	CcSEcCtD
Melphalan—Skin disorder—Docetaxel—prostate cancer	3.1e-05	0.000372	CcSEcCtD
Melphalan—Oedema—Capecitabine—prostate cancer	3.09e-05	0.000371	CcSEcCtD
Melphalan—Infection—Capecitabine—prostate cancer	3.07e-05	0.000368	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—prostate cancer	3.06e-05	0.000367	CcSEcCtD
Melphalan—Urticaria—Etoposide—prostate cancer	3.05e-05	0.000366	CcSEcCtD
Melphalan—Haemoglobin—Epirubicin—prostate cancer	3.04e-05	0.000365	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—prostate cancer	3.04e-05	0.000365	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—prostate cancer	3.04e-05	0.000365	CcSEcCtD
Melphalan—Anorexia—Docetaxel—prostate cancer	3.04e-05	0.000365	CcSEcCtD
Melphalan—Hepatitis—Epirubicin—prostate cancer	3.03e-05	0.000363	CcSEcCtD
Melphalan—Haemorrhage—Epirubicin—prostate cancer	3.03e-05	0.000363	CcSEcCtD
Melphalan—Thrombocytopenia—Capecitabine—prostate cancer	3.02e-05	0.000363	CcSEcCtD
Melphalan—Tachycardia—Capecitabine—prostate cancer	3.01e-05	0.000362	CcSEcCtD
Melphalan—Skin disorder—Capecitabine—prostate cancer	3e-05	0.00036	CcSEcCtD
Melphalan—Urinary tract disorder—Epirubicin—prostate cancer	2.99e-05	0.000359	CcSEcCtD
Melphalan—Hypotension—Docetaxel—prostate cancer	2.98e-05	0.000358	CcSEcCtD
Melphalan—Connective tissue disorder—Epirubicin—prostate cancer	2.98e-05	0.000357	CcSEcCtD
Melphalan—Urethral disorder—Epirubicin—prostate cancer	2.97e-05	0.000356	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—prostate cancer	2.95e-05	0.000354	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—CREBBP—prostate cancer	2.94e-05	0.00117	CbGpPWpGaD
Melphalan—Anorexia—Capecitabine—prostate cancer	2.94e-05	0.000353	CcSEcCtD
Melphalan—Nausea—Estradiol—prostate cancer	2.94e-05	0.000353	CcSEcCtD
Melphalan—Vomiting—Mitoxantrone—prostate cancer	2.93e-05	0.000352	CcSEcCtD
Melphalan—Convulsion—Prednisone—prostate cancer	2.92e-05	0.000351	CcSEcCtD
Melphalan—Rash—Mitoxantrone—prostate cancer	2.91e-05	0.000349	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—IGF1—prostate cancer	2.91e-05	0.00116	CbGpPWpGaD
Melphalan—Dermatitis—Mitoxantrone—prostate cancer	2.91e-05	0.000349	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.91e-05	0.000349	CcSEcCtD
Melphalan—Hypotension—Capecitabine—prostate cancer	2.89e-05	0.000346	CcSEcCtD
Melphalan—Myalgia—Prednisone—prostate cancer	2.87e-05	0.000344	CcSEcCtD
Melphalan—Paraesthesia—Docetaxel—prostate cancer	2.87e-05	0.000344	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.85e-05	0.000342	CcSEcCtD
Melphalan—Dyspnoea—Docetaxel—prostate cancer	2.84e-05	0.000341	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—PRKACB—prostate cancer	2.83e-05	0.00113	CbGpPWpGaD
Melphalan—Hypersensitivity—Etoposide—prostate cancer	2.83e-05	0.000339	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—prostate cancer	2.82e-05	0.000338	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.81e-05	0.000338	CcSEcCtD
Melphalan—Flushing—Epirubicin—prostate cancer	2.81e-05	0.000337	CcSEcCtD
Melphalan—Dyspepsia—Docetaxel—prostate cancer	2.81e-05	0.000337	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—prostate cancer	2.8e-05	0.000336	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—prostate cancer	2.8e-05	0.000336	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—PIK3CD—prostate cancer	2.79e-05	0.00111	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—B4GALT4—prostate cancer	2.78e-05	0.0011	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HPGD—prostate cancer	2.78e-05	0.0011	CbGpPWpGaD
Melphalan—Paraesthesia—Capecitabine—prostate cancer	2.77e-05	0.000333	CcSEcCtD
Melphalan—Decreased appetite—Docetaxel—prostate cancer	2.77e-05	0.000333	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—prostate cancer	2.77e-05	0.000332	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—SERPINE1—prostate cancer	2.76e-05	0.0011	CbGpPWpGaD
Melphalan—Gastrointestinal disorder—Docetaxel—prostate cancer	2.75e-05	0.000331	CcSEcCtD
Melphalan—Asthenia—Etoposide—prostate cancer	2.75e-05	0.000331	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Dyspnoea—Capecitabine—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Oedema—Prednisone—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Anaphylactic shock—Prednisone—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Fatigue—Docetaxel—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—prostate cancer	2.75e-05	0.00033	CcSEcCtD
Melphalan—Nausea—Mitoxantrone—prostate cancer	2.74e-05	0.000329	CcSEcCtD
Melphalan—Immune system disorder—Epirubicin—prostate cancer	2.74e-05	0.000328	CcSEcCtD
Melphalan—Infection—Prednisone—prostate cancer	2.73e-05	0.000328	CcSEcCtD
Melphalan—Mediastinal disorder—Epirubicin—prostate cancer	2.73e-05	0.000328	CcSEcCtD
Melphalan—Pain—Docetaxel—prostate cancer	2.73e-05	0.000327	CcSEcCtD
Melphalan—Dyspepsia—Capecitabine—prostate cancer	2.72e-05	0.000326	CcSEcCtD
Melphalan—Pruritus—Etoposide—prostate cancer	2.72e-05	0.000326	CcSEcCtD
Melphalan—Arrhythmia—Epirubicin—prostate cancer	2.71e-05	0.000325	CcSEcCtD
Melphalan—Tachycardia—Prednisone—prostate cancer	2.69e-05	0.000322	CcSEcCtD
Melphalan—Decreased appetite—Capecitabine—prostate cancer	2.69e-05	0.000322	CcSEcCtD
Melphalan—Alopecia—Epirubicin—prostate cancer	2.68e-05	0.000321	CcSEcCtD
Melphalan—Skin disorder—Prednisone—prostate cancer	2.67e-05	0.000321	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—NCOA2—prostate cancer	2.67e-05	0.00106	CbGpPWpGaD
Melphalan—Gastrointestinal disorder—Capecitabine—prostate cancer	2.67e-05	0.00032	CcSEcCtD
Melphalan—Fatigue—Capecitabine—prostate cancer	2.66e-05	0.00032	CcSEcCtD
Melphalan—Pain—Capecitabine—prostate cancer	2.64e-05	0.000317	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—NOS3—prostate cancer	2.64e-05	0.00105	CbGpPWpGaD
Melphalan—Diarrhoea—Etoposide—prostate cancer	2.63e-05	0.000315	CcSEcCtD
Melphalan—Anorexia—Prednisone—prostate cancer	2.62e-05	0.000315	CcSEcCtD
Melphalan—SLC22A3—Metabolism—TNFRSF21—prostate cancer	2.61e-05	0.00104	CbGpPWpGaD
Melphalan—Flushing—Doxorubicin—prostate cancer	2.6e-05	0.000312	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—JAK2—prostate cancer	2.56e-05	0.00102	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.55e-05	0.00101	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	2.55e-05	0.00101	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MTAP—prostate cancer	2.54e-05	0.00101	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP7B1—prostate cancer	2.54e-05	0.00101	CbGpPWpGaD
Melphalan—Immune system disorder—Doxorubicin—prostate cancer	2.53e-05	0.000304	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—prostate cancer	2.53e-05	0.000303	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Prednisone—prostate cancer	2.51e-05	0.000301	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—prostate cancer	2.5e-05	0.0003	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—prostate cancer	2.48e-05	0.000297	CcSEcCtD
Melphalan—SLC22A3—Metabolism—SULT1E1—prostate cancer	2.47e-05	0.000985	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SRD5A1—prostate cancer	2.47e-05	0.000985	CbGpPWpGaD
Melphalan—Paraesthesia—Prednisone—prostate cancer	2.47e-05	0.000296	CcSEcCtD
Melphalan—Urticaria—Capecitabine—prostate cancer	2.45e-05	0.000294	CcSEcCtD
Melphalan—Vomiting—Etoposide—prostate cancer	2.44e-05	0.000293	CcSEcCtD
Melphalan—Anaemia—Epirubicin—prostate cancer	2.44e-05	0.000292	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—PIK3CB—prostate cancer	2.43e-05	0.000969	CbGpPWpGaD
Melphalan—Dyspepsia—Prednisone—prostate cancer	2.42e-05	0.000291	CcSEcCtD
Melphalan—Rash—Etoposide—prostate cancer	2.42e-05	0.00029	CcSEcCtD
Melphalan—Dermatitis—Etoposide—prostate cancer	2.42e-05	0.00029	CcSEcCtD
Melphalan—Decreased appetite—Prednisone—prostate cancer	2.39e-05	0.000287	CcSEcCtD
Melphalan—Fatigue—Prednisone—prostate cancer	2.37e-05	0.000285	CcSEcCtD
Melphalan—Leukopenia—Epirubicin—prostate cancer	2.36e-05	0.000283	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ACSL4—prostate cancer	2.36e-05	0.00094	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HSD17B3—prostate cancer	2.36e-05	0.00094	CbGpPWpGaD
Melphalan—Hypersensitivity—Docetaxel—prostate cancer	2.35e-05	0.000282	CcSEcCtD
Melphalan—Cough—Epirubicin—prostate cancer	2.3e-05	0.000276	CcSEcCtD
Melphalan—Asthenia—Docetaxel—prostate cancer	2.29e-05	0.000275	CcSEcCtD
Melphalan—Convulsion—Epirubicin—prostate cancer	2.28e-05	0.000274	CcSEcCtD
Melphalan—Nausea—Etoposide—prostate cancer	2.28e-05	0.000274	CcSEcCtD
Melphalan—Hypersensitivity—Capecitabine—prostate cancer	2.28e-05	0.000273	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ARG2—prostate cancer	2.26e-05	0.000901	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—UMPS—prostate cancer	2.26e-05	0.000901	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PHGDH—prostate cancer	2.26e-05	0.000901	CbGpPWpGaD
Melphalan—Pruritus—Docetaxel—prostate cancer	2.26e-05	0.000271	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—prostate cancer	2.26e-05	0.000271	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.25e-05	0.000896	CbGpPWpGaD
Melphalan—Myalgia—Epirubicin—prostate cancer	2.24e-05	0.000269	CcSEcCtD
Melphalan—Chest pain—Epirubicin—prostate cancer	2.24e-05	0.000269	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—IL2—prostate cancer	2.24e-05	0.00089	CbGpPWpGaD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.23e-05	0.000268	CcSEcCtD
Melphalan—SLC22A3—Metabolism—LDHB—prostate cancer	2.22e-05	0.000883	CbGpPWpGaD
Melphalan—Asthenia—Capecitabine—prostate cancer	2.22e-05	0.000266	CcSEcCtD
Melphalan—Urticaria—Prednisone—prostate cancer	2.19e-05	0.000262	CcSEcCtD
Melphalan—Pruritus—Capecitabine—prostate cancer	2.19e-05	0.000262	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—prostate cancer	2.18e-05	0.000262	CcSEcCtD
Melphalan—Diarrhoea—Docetaxel—prostate cancer	2.18e-05	0.000262	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CYP3A5—prostate cancer	2.18e-05	0.000867	CbGpPWpGaD
Melphalan—Oedema—Epirubicin—prostate cancer	2.15e-05	0.000258	CcSEcCtD
Melphalan—Anaphylactic shock—Epirubicin—prostate cancer	2.15e-05	0.000258	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—RXRA—prostate cancer	2.14e-05	0.000852	CbGpPWpGaD
Melphalan—Infection—Epirubicin—prostate cancer	2.14e-05	0.000257	CcSEcCtD
Melphalan—Cough—Doxorubicin—prostate cancer	2.13e-05	0.000255	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—prostate cancer	2.11e-05	0.000254	CcSEcCtD
Melphalan—Diarrhoea—Capecitabine—prostate cancer	2.11e-05	0.000254	CcSEcCtD
Melphalan—Thrombocytopenia—Epirubicin—prostate cancer	2.11e-05	0.000253	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PDHA1—prostate cancer	2.1e-05	0.000837	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTA3—prostate cancer	2.1e-05	0.000837	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—UCP3—prostate cancer	2.1e-05	0.000837	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TCN2—prostate cancer	2.1e-05	0.000837	CbGpPWpGaD
Melphalan—Tachycardia—Epirubicin—prostate cancer	2.1e-05	0.000252	CcSEcCtD
Melphalan—Skin disorder—Epirubicin—prostate cancer	2.09e-05	0.000251	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—prostate cancer	2.08e-05	0.000249	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—prostate cancer	2.08e-05	0.000249	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.06e-05	0.000248	CcSEcCtD
Melphalan—Anorexia—Epirubicin—prostate cancer	2.05e-05	0.000246	CcSEcCtD
Melphalan—Vomiting—Docetaxel—prostate cancer	2.03e-05	0.000243	CcSEcCtD
Melphalan—Hypersensitivity—Prednisone—prostate cancer	2.03e-05	0.000243	CcSEcCtD
Melphalan—Rash—Docetaxel—prostate cancer	2.01e-05	0.000241	CcSEcCtD
Melphalan—Hypotension—Epirubicin—prostate cancer	2.01e-05	0.000241	CcSEcCtD
Melphalan—Dermatitis—Docetaxel—prostate cancer	2.01e-05	0.000241	CcSEcCtD
Melphalan—SLC22A3—Metabolism—HSD3B1—prostate cancer	2.01e-05	0.000799	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—EP300—prostate cancer	2.01e-05	0.000798	CbGpPWpGaD
Melphalan—Anaphylactic shock—Doxorubicin—prostate cancer	1.99e-05	0.000239	CcSEcCtD
Melphalan—Oedema—Doxorubicin—prostate cancer	1.99e-05	0.000239	CcSEcCtD
Melphalan—Infection—Doxorubicin—prostate cancer	1.98e-05	0.000237	CcSEcCtD
Melphalan—Asthenia—Prednisone—prostate cancer	1.97e-05	0.000237	CcSEcCtD
Melphalan—Vomiting—Capecitabine—prostate cancer	1.96e-05	0.000236	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.96e-05	0.000235	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—SRC—prostate cancer	1.95e-05	0.000776	CbGpPWpGaD
Melphalan—Thrombocytopenia—Doxorubicin—prostate cancer	1.95e-05	0.000234	CcSEcCtD
Melphalan—Rash—Capecitabine—prostate cancer	1.95e-05	0.000234	CcSEcCtD
Melphalan—Pruritus—Prednisone—prostate cancer	1.95e-05	0.000234	CcSEcCtD
Melphalan—Dermatitis—Capecitabine—prostate cancer	1.95e-05	0.000233	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—prostate cancer	1.94e-05	0.000233	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—prostate cancer	1.93e-05	0.000232	CcSEcCtD
Melphalan—Paraesthesia—Epirubicin—prostate cancer	1.93e-05	0.000232	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GSTA4—prostate cancer	1.92e-05	0.000766	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TBXAS1—prostate cancer	1.92e-05	0.000766	CbGpPWpGaD
Melphalan—Dyspnoea—Epirubicin—prostate cancer	1.92e-05	0.00023	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—VEGFA—prostate cancer	1.9e-05	0.000756	CbGpPWpGaD
Melphalan—Anorexia—Doxorubicin—prostate cancer	1.9e-05	0.000228	CcSEcCtD
Melphalan—Nausea—Docetaxel—prostate cancer	1.9e-05	0.000227	CcSEcCtD
Melphalan—Dyspepsia—Epirubicin—prostate cancer	1.89e-05	0.000227	CcSEcCtD
Melphalan—Diarrhoea—Prednisone—prostate cancer	1.88e-05	0.000226	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GSTA2—prostate cancer	1.87e-05	0.000746	CbGpPWpGaD
Melphalan—Decreased appetite—Epirubicin—prostate cancer	1.87e-05	0.000224	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—prostate cancer	1.86e-05	0.000223	CcSEcCtD
Melphalan—Gastrointestinal disorder—Epirubicin—prostate cancer	1.86e-05	0.000223	CcSEcCtD
Melphalan—Fatigue—Epirubicin—prostate cancer	1.86e-05	0.000223	CcSEcCtD
Melphalan—SLC22A3—Metabolism—SULT1A1—prostate cancer	1.85e-05	0.000737	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCG5—prostate cancer	1.85e-05	0.000737	CbGpPWpGaD
Melphalan—Pain—Epirubicin—prostate cancer	1.84e-05	0.000221	CcSEcCtD
Melphalan—Nausea—Capecitabine—prostate cancer	1.83e-05	0.00022	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.81e-05	0.000218	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GSTA1—prostate cancer	1.81e-05	0.00072	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTO1—prostate cancer	1.79e-05	0.000712	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HSD3B2—prostate cancer	1.79e-05	0.000712	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NAT2—prostate cancer	1.79e-05	0.000712	CbGpPWpGaD
Melphalan—Paraesthesia—Doxorubicin—prostate cancer	1.79e-05	0.000215	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—prostate cancer	1.78e-05	0.000213	CcSEcCtD
Melphalan—Dyspepsia—Doxorubicin—prostate cancer	1.75e-05	0.00021	CcSEcCtD
Melphalan—Vomiting—Prednisone—prostate cancer	1.75e-05	0.00021	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—TGFB1—prostate cancer	1.74e-05	0.000694	CbGpPWpGaD
Melphalan—Rash—Prednisone—prostate cancer	1.73e-05	0.000208	CcSEcCtD
Melphalan—Dermatitis—Prednisone—prostate cancer	1.73e-05	0.000208	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—prostate cancer	1.73e-05	0.000208	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.72e-05	0.000206	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—prostate cancer	1.72e-05	0.000206	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CYP2C18—prostate cancer	1.71e-05	0.000683	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—LRP2—prostate cancer	1.71e-05	0.000683	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PLCB2—prostate cancer	1.71e-05	0.000683	CbGpPWpGaD
Melphalan—Urticaria—Epirubicin—prostate cancer	1.71e-05	0.000205	CcSEcCtD
Melphalan—Pain—Doxorubicin—prostate cancer	1.7e-05	0.000204	CcSEcCtD
Melphalan—SLC22A3—Metabolism—P4HB—prostate cancer	1.68e-05	0.000669	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC22A1—prostate cancer	1.64e-05	0.000651	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—PPARA—prostate cancer	1.64e-05	0.000651	CbGpPWpGaD
Melphalan—Nausea—Prednisone—prostate cancer	1.63e-05	0.000196	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—KRAS—prostate cancer	1.61e-05	0.000643	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SULT2A1—prostate cancer	1.59e-05	0.000635	CbGpPWpGaD
Melphalan—Hypersensitivity—Epirubicin—prostate cancer	1.59e-05	0.00019	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—prostate cancer	1.58e-05	0.00019	CcSEcCtD
Melphalan—SLC22A3—Metabolism—MED12—prostate cancer	1.57e-05	0.000624	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GNG5—prostate cancer	1.56e-05	0.000619	CbGpPWpGaD
Melphalan—Asthenia—Epirubicin—prostate cancer	1.54e-05	0.000185	CcSEcCtD
Melphalan—Pruritus—Epirubicin—prostate cancer	1.52e-05	0.000183	CcSEcCtD
Melphalan—SLC22A3—Metabolism—NCOA3—prostate cancer	1.5e-05	0.000597	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—prostate cancer	1.48e-05	0.000591	CbGpPWpGaD
Melphalan—Diarrhoea—Epirubicin—prostate cancer	1.47e-05	0.000177	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—prostate cancer	1.47e-05	0.000176	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—TP53—prostate cancer	1.44e-05	0.000571	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HPGDS—prostate cancer	1.43e-05	0.000569	CbGpPWpGaD
Melphalan—Asthenia—Doxorubicin—prostate cancer	1.43e-05	0.000171	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CYP2C19—prostate cancer	1.42e-05	0.000566	CbGpPWpGaD
Melphalan—Pruritus—Doxorubicin—prostate cancer	1.41e-05	0.000169	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ACHE—prostate cancer	1.39e-05	0.000552	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTT1—prostate cancer	1.39e-05	0.000552	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP2A6—prostate cancer	1.37e-05	0.000546	CbGpPWpGaD
Melphalan—Vomiting—Epirubicin—prostate cancer	1.37e-05	0.000164	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—prostate cancer	1.36e-05	0.000163	CcSEcCtD
Melphalan—Rash—Epirubicin—prostate cancer	1.36e-05	0.000163	CcSEcCtD
Melphalan—Dermatitis—Epirubicin—prostate cancer	1.36e-05	0.000163	CcSEcCtD
Melphalan—SLC22A3—Metabolism—AKR1C3—prostate cancer	1.33e-05	0.000531	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PRKACB—prostate cancer	1.33e-05	0.000528	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP17A1—prostate cancer	1.31e-05	0.000523	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.3e-05	0.000517	CbGpPWpGaD
Melphalan—Nausea—Epirubicin—prostate cancer	1.28e-05	0.000153	CcSEcCtD
Melphalan—Vomiting—Doxorubicin—prostate cancer	1.27e-05	0.000152	CcSEcCtD
Melphalan—Rash—Doxorubicin—prostate cancer	1.26e-05	0.000151	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—prostate cancer	1.25e-05	0.000151	CcSEcCtD
Melphalan—SLC22A3—Metabolism—NCOA2—prostate cancer	1.25e-05	0.000498	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—AKT1—prostate cancer	1.21e-05	0.000482	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC5A5—prostate cancer	1.19e-05	0.000475	CbGpPWpGaD
Melphalan—Nausea—Doxorubicin—prostate cancer	1.18e-05	0.000142	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CYP2E1—prostate cancer	1.17e-05	0.000464	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NQO1—prostate cancer	1.15e-05	0.000459	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TH—prostate cancer	1.14e-05	0.000452	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP3A4—prostate cancer	1.12e-05	0.000447	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1B1—prostate cancer	1.1e-05	0.00044	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GGT1—prostate cancer	1.07e-05	0.000426	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NCOA1—prostate cancer	1.05e-05	0.00042	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP19A1—prostate cancer	1.04e-05	0.000414	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—RXRA—prostate cancer	1e-05	0.000399	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—COMT—prostate cancer	9.66e-06	0.000385	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTP1—prostate cancer	9.61e-06	0.000383	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ITPR1—prostate cancer	9.46e-06	0.000377	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TYMS—prostate cancer	8.94e-06	0.000356	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTM1—prostate cancer	8.83e-06	0.000352	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—LPL—prostate cancer	8.67e-06	0.000345	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1A1—prostate cancer	8.37e-06	0.000333	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ERCC2—prostate cancer	8.31e-06	0.000331	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MTHFR—prostate cancer	7.81e-06	0.000311	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PPARA—prostate cancer	7.66e-06	0.000305	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CAV1—prostate cancer	7.2e-06	0.000287	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CG—prostate cancer	6.56e-06	0.000261	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—INS—prostate cancer	6.21e-06	0.000247	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CREBBP—prostate cancer	6.08e-06	0.000242	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CD—prostate cancer	5.77e-06	0.00023	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NOS3—prostate cancer	5.45e-06	0.000217	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CB—prostate cancer	5.03e-06	0.0002	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTGS2—prostate cancer	4.98e-06	0.000198	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTEN—prostate cancer	4.34e-06	0.000173	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—EP300—prostate cancer	4.14e-06	0.000165	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—prostate cancer	3.06e-06	0.000122	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AKT1—prostate cancer	2.5e-06	9.96e-05	CbGpPWpGaD
